Nebula Research & Development LLC Trims Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Nebula Research & Development LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 43.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,670 shares of the company's stock after selling 2,035 shares during the period. Nebula Research & Development LLC's holdings in Krystal Biotech were worth $418,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. FMR LLC boosted its holdings in Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. increased its stake in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. Hood River Capital Management LLC boosted its stake in shares of Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after acquiring an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock worth $79,812,000 after acquiring an additional 71,200 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several recent research reports. HC Wainwright lifted their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday, April 28th. Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $222.71.

Krystal Biotech Stock Down 1.0 %

Shares of NASDAQ:KRYS traded down $1.59 during trading on Monday, reaching $164.58. 54,309 shares of the company traded hands, compared to its average volume of 293,597. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The company's 50 day moving average is $174.92 and its two-hundred day moving average is $171.22. The firm has a market capitalization of $4.76 billion, a PE ratio of 55.04 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.30 EPS. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).